An Immunobridging study to evaluate the neutralizing antibody titer in adults

1

immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or 2 **MVC-COV1901.** 3 4 Josue Antonio Estrada¹, Chien-Yu Cheng^{2,3,*}, Shin-Yen Ku⁴, Hui-Chun Hu⁴, Hsiu-Wen Yeh⁴, 5 Yi-Chun Lin², Cheng-Pin Chen^{2,5}, Shu-Hsing Cheng^{2,6}, I-Feng Lin^{3**} 6 7 ¹ Medigen Vaccine Biologics, Taipei, Taiwan 8 ² Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, 9 10 Taoyuan, Taiwan ³ Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University 11 12 ⁴ Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, 13 Taiwan ⁵ School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan 14 ⁶ School of Public Health, Taipei Medical University, Taipei, Taiwan 15 16 17 *Corresponding author: Chien-Yu Cheng, Division of Infectious Diseases, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, No. 1492, Zhongshan Rd., 18 Taoyuan Dist., Taoyuan City 330, Taiwan (R.O.C.), Tel: +886-3-3699721, E-mail: 19 s841060@gm.ym.edu.tw 20

21 **Alternative corresponding author: I-Feng Lin Prof. Institute of Public Health, School of

- 22 Medicine National Yang-Ming Chiao Tung University, 155 Li-Nong Street, Pei-Tou, Taipei, Taiwan
- 23 R.O.C <u>Tel:</u> +886-2-28267311, <u>E-mail: iflin@nycu.edu.tw</u>

24 Abstract

25 Background

26 Rapid development and deployment of vaccine is crucial to control the continuously evolving 27 COVID-19 pandemic. Placebo-controlled phase 3 efficacy trial is still standard for authorizing 28 vaccines in majority of the world. However, due to lack of cases or participants in parts of the world, 29 this has not always been feasible. An alternative to efficacy trial is immunobridging, in which the 30 immune response or correlates of protection of a vaccine candidate is compared against an approved 31 vaccine. Here we describe a case study where our candidate vaccine, MVC-COV1901, has been 32 granted for emergency use authorization (EUA) locally based on the non-inferiority immunobridging 33 process.

34 Methods

The per protocol immunogenicity (PPI) subset from the MVC-COV1901 phase 2 trial was used for this study and consisted of 903 subjects who have received two doses of MVC-COV1901 as scheduled in the clinical trial. The comparator set of population consisted of 200 subjects of \geq 20 years of age who were generally healthy and have received two doses of AstraZeneca ChAdOx nCOV-19 (AZD1222) recruited from Taoyuan General Hospital, Ministry of Health and Welfare.

40 **Results**

MVC-COV1901 was shown to have a geometric mean titer (GMT) ratio lower bound 95% confidence interval (CI) of 3.4 against the comparator vaccine and a seroconversion rate of 95.5% at the 95% CI lower bound, which both exceeded the criteria set by the Taiwan regulatory authority for EUA approval. These results supported the EUA approval of MVC-COV1901 by the Taiwanese regulatory authority in July 2021. Following the consensus of the International Coalition of Medicines Regulatory Authorities (ICMRA), countries from the Access Consortium has recently adopted the use of immunobridging studies as acceptable for authorizing COVID-19 vaccines in lieu of efficacy data.

- 48
- 49

50 Conclusion

- 51 The data presented in the study showed that it is reasonably likely that the vaccine efficacy of
- 52 MVC-COV1901 is similar or superior to that of AZ. Data could be used in support of further vaccine
- 53 development and regulatory approval.

54 Introduction

55 MVC-COV1901 is a protein subunit SARS-CoV-2 vaccine based on the stabilized prefusion spike 56 protein S-2P adjuvanted with CpG 1080 [1]. From 2020 to early 2021, Taiwan has been spared from 57 the worst of the pandemic, which recorded only a total of local and imported of 525 cases in 2020 and 58 339 cases in 2021 prior to the local outbreak in May 2021 [2]. As a result, it was not feasible to conduct 59 placebo-controlled efficacy trial locally in Taiwan at the time. In response, Taiwan health authorities 60 designed a pathway to EUA for all local vaccine candidates based on immunobridging, which 61 compares the immune response of a vaccine candidate with an approved vaccine for comparison [3]. 62 Over 3,800 participants were enrolled in a phase 2 clinical trial for MVC-COV1901 and the results of 63 this large-scale phase 2 trial allowed the Taiwan regulatory authorities to examine the safety and 64 immunogenicity to the comparator vaccine which has already been approved in Taiwan for 65 non-inferiority [3, 4]. MVC-COV1901 was approved by the Taiwan Food and Drug Administration 66 (TFDA) in July 2021, making it among the first COVID-19 vaccine approved using immunobridging 67 study prior to the availability of efficacy data [5]. In June 2021, experts from regulatory authorities 68 around the world convened at a workshop for the future of COVID-19 vaccine development, and 69 consensus was reached for the use of well-justified and appropriately designed immunobridging 70 studies in place of clinical endpoint efficacy studies when they are not feasible [6]. In September 2021, 71 the consensus position has since been taken up by the Access Consortium, which consisted of 72 regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland, to accept 73 immunobridging studies as sufficient for authorizing COVID-19 vaccines in these countries [7, 8]. 74 This manuscript thus illustrates an example of a COVID-19 vaccine approved with immunobridging 75 study, which has gradually become recognized by health regulatory authorities worldwide.

- 76
- 77
- 78

79

80 Methods

81 Clinical trial and sample population

82 The MVC-COV1901 phase 2 trial was a prospective, randomized, double-blind, 83 placebo-controlled, and multicenter study to evaluate the safety, tolerability, and immunogenicity of 84 the SARS-CoV-2 vaccine candidate MVC-COV1901 (NCT04695652) [4]. The main study of the trial 85 consisted of 3,844 subjects of ≥ 20 years of age who were generally healthy or with stable pre-existing 86 medical conditions recruited from eleven sites in Taiwan, and this population was used for safety 87 analysis [4]. The per protocol immunogenicity (PPI) subset from the MVC-COV1901 phase 2 trial was 88 used for this study and consisted of 903 subjects who have received two doses of MVC-COV1901 as 89 scheduled in the clinical trial. The comparator set of population consisted of 200 subjects of \geq 20 years 90 of age who were generally healthy and have received two doses of AstraZeneca ChAdOx nCOV-19 91 (AZD1222) recruited from Taoyuan General Hospital, Ministry of Health and Welfare. 92 The trial protocol and informed consent form were approved by the Taiwan Food and Drug 93 Administration (FDA) and the ethics committees at the participating sites. The institutional review 94 boards included the Chang Gung Medical Foundation, National Taiwan University Hospital, Taipei 95 Veterans General Hospital, Tri-Service General Hospital, Taipei Medical University Hospital, Taipei 96 Municipal Wanfang Hospital, Taoyuan General Hospital Ministry of Health and Welfare, China 97 Medical University Hospital, Changhua Christian Hospital, National Cheng Kung University Hospital, 98 and Kaoshiung Medical University Hospital. The trial was done in accordance with the principles of 99 the Declaration of Helsinki and good clinical practice guidelines.

100

101 Vaccines

Medigen COVID-19 vaccine or MVC-COV1901, a subunit vaccine consisting of the prefusion
spike protein (S-2P) adjuvanted with 750 µg CpG 1018 and 375 µg aluminum hydroxide. A standard
0.5 mL dose contains 15 µg of the Spike-2P. Both are delivered instramuscularly at the deltoid region.
The comparator vaccine is ChAdOxAZD1222, an adenoviral vector vaccine developed by Oxford

106 University and AstraZeneca served at multi-dose vials. Each dose of vaccine is 0.5 mL and contains 107 5×10^{10} viral particles.

108

109 Immunobridging study

According to the TFDA document, the follow criteria were set for a candidate vaccine to be granted EUA in Taiwan [3]:

- Clinical data: Immunobridging study to evaluate the immunogenicity of locally developed
 vaccine against a comparator vaccine which has already been approved in Taiwan.
- Safety data: At least 3,000 subjects were required to be tracked for at least one month for
 safety data after the last dose and all subjects to be followed for a median of two months
 after the last dose.

As the AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine was the first COVID-19 vaccine to be approved in Taiwan, it was chosen as the comparator vaccine for which the locally developed vaccines are to be benchmarked with [3]. The immunobridging criteria were to fulfill the following endpoints for serum samples 28 days after the second dose (Day 57) in population under the age of 65 [3, 9]:

- The lower limit of the 95% confidence interval of the geometric mean titer ratio (GMTR)
 of the prototype strain live virus neutralizing antibodies for the MVC-COVID19 vaccine
 group to the external control group must be greater than 0.67, as shown in a blood test 28
 days after the second dose;
- 125 2. The sero-response level was defined as the neutralizing antibody titers against the 126 prototype strain live virus at 28 days after receiving the second dose of the vaccine, at the 127 referred point of 60% reverse accumulative distribution curve for external control group 128 The lower limit of the 95% confidence interval for the sero-response rate (the proportion of 129 subjects whose neutralizing antibody titers against the prototype strain live virus, at 28 130 days after receiving the second dose of the MVC-COVID19 vaccine are above the 131 sero-response level) must be greater than 50%

132 Live SARS CoV 2 neutralization assay

- 133 Neutralizing antibody titers against the Wuhan prototype SAR-CoV-2 were determined by
- 134 SARS-CoV-2 live virus neutralization assay as described previously [4].
- 135

136 Statistical analysis

137 Descriptive statistics were obtained and presented for the population's characteristics. GMTs 138 were estimated from neutralizing antibody titers measured at 28 days after the second dose of the study 139 intervention. Geometric mean titer ratio (GMTR) is calculated as the GMT of MVC group over the 140 GMT of AZ group.

141 The GMTs are presented with their two-sided 95% CI. To assess the magnitudes of differences in 142 immune response between the two vaccines, an analysis of covariance (ANCOVA) model was used. 143 The model included the log-transformed antibody titers at Day 57 as the dependent variable, vaccine 144 group (AZD1222 and MVC-COV1901) as an explanatory variable and adjusted for age, BMI, gender 145 and comorbidity profile. The 95% CI for the adjusted neutralizing antibody titers of each vaccine 146 group were obtained. Then adjusted GMT and corresponding 95% CI were back-transformed to the 147 original scale. A worst modified subset of the sample was created which included only GMT values \leq 148 67th percentile at Day 57. Reverse cumulative distribution (RCD) curves were constructed for data 28 days after the 2nd dose for the AZD1222 and MVC-COV1901 groups. 149

150

151 **Results**

152 **Demographics**

The mean age of AZD1222 (AZ) and MVC-COV1901 (MVC) groups were similar at 42.9 and 45.7 years, respectively (Table 1). However, only six (3%) subjects were over age of 65 in the AZ group compared to 221 (24.4%) in MVC-COV1901, though this is due to the study design of the MVC-COV1901 trial to enroll at least 20% of participants to be over age of 65 [4]. In terms of gender, the AZ group had higher percentage of females (59.8%) than that of MVC group (42.3%). Other

discrepancies between the two groups include the higher proportion of comorbidity in the AZ group (38.1%) compared to the MVC group (19.3%). In order to investigate the effects of these factors for the immunobridging process, we performed sensitivity analyses based on age group, gender, and comorbidity.

162

163 **Immunogenicity**

164 In subjects of under age of 64, at 28 days after the second dose, the AZ and MVC groups had 165 GMTs of 186 and 733, respectively (Figure 1). When including the above 65 years of age into the 166 GMT calculation, the GMTs decreased to 184 and 662 for the AZ and MVC groups, respectively, due 167 to the inclusion of lower neutralizing antibody titer levels in the older age group (Figure 1). According 168 to the analysis for immunobridging study, the results showed that the lower limit of the 95% CI for the 169 GMTR of the prototype strain live virus neutralizing antibodies between MVC and AZ groups was 3.4 170 times, which was greater than the requirement of 0.67 times. The lower limit of the 95% confidence 171 interval for the sero-response rate of the MVC group was 95.5%, which was greater than the 172 requirement of 50%.

Illustrated in Figure 2 are the reverse cumulative distribution (RCD) curves of neutralizing antibody titers. Higher neutralizing antibody titers were observed in the MVC group. At the referred point of 60% for the AZ group, participants had neutralizing antibody titers equal to or less than 199.5 IU/mL. This is equivalent to approximately 90% of individuals given MVC.

177 Sensitivity Analysis

The sensitivity analyses conducted to detect the robustness of GMT results reveal that both AZD1222 and MVC-COV1901 enhanced neutralizing antibody titers in both the subset of the younger individuals (aged 20-64 years) and the overall sample which includes older participants aged 65 years and above. The GMT Ratio (AZ vs. MVC) in the younger group which was 3.89 (95% CI: 3.45, 4.4) was comparable to the overall GMT Ratio of 3.55 (3.2, 3.97). The subgroup of younger individuals had higher GMTs for both AZ (185.97; 95% CI: 167.3, 206.7) and MVC (723.6; 95% CI: 683.7, 765.8)

⁹

184 as compared to the overall GMTs for AZ (184.05; 95%CI: 166.5, 204.7) and MVC (654.07; 95% CI: 185 620.9, 689.03). Adjusting for age, sex, Body Mass Index (BMI) and comorbidity status, the population 186 including 65 years and above has a more robust MVC response albeit comparable to those in the 187 younger age group. The GMT ratio (MVC vs. AZ) in the overall sample is 3.80 (95% CI: 3.4, 4.3) 188 while that of the younger subset is 3.78 (95% CI: 3.3, 4.3). Adjusted GMTs also indicate a better 189 response among the younger age group (Table 2). Findings are consistent when looking at the worst 190 modified subset of the sample (i.e. Day 57 titer \leq 67th percentile). GMTs are lower in the overall 191 sample which includes those 65 years and above, than in the younger group (Table 3). Adjusted GMT 192 ratio is also comparable between the overall sample (2.70; 95% CI: 2.4,3.01) and the younger age 193 group (2.69; 95% CI: 2.4, 3.02). Subgroup analyses based on gender and comorbidity profile show 194 consistency in estimates across subgroups.

195

196 Discussion

197 The major regulators considered that the evidence from studies with authorized COVID-19 198 vaccines is sufficient to support using neutralizing antibody titers as primary endpoint in an 199 immunogenicity bridging study for authoring new COVID-19 vaccines. The decision had become 200 relevant when clinical endpoint efficacy studies are less feasible. Our study followed the statement 201 made by The International Coalition of Medicines Regulatory Authorities (ICMRA) [10] 202 demonstrating the superiority of immunogenicity of MVC-COV1901 against AZ to predict vaccine 203 effectiveness.

The regulator's consortium recommended that the study design should be non-inferiority when the choice of the active comparator has demonstrated high efficacy, or superiority if the active comparator has modest efficacy. AZ being a product that has modest efficacy justified the need for demonstrating the superiority to gain regulatory approval. Our study tried to simulate the immunogenicity comparison between MVC-COV1901 and AZ done by the regulator in Taiwan through which a EUA was granted to the former vaccine. The comparative study was not done in a

210 randomized, blinded study, but an external comparison. To increase confidence from the regulator's 211 perspective, a series of sensitivity analyses were conducted. The data showed that after omitting the 212 highest 33 percent data points of neutralizing antibody titers, the results can still hold.

The neutralizing antibody titers were determined using World Health Organization (WHO)-certified reference standards, International Unit, IU/mL. The use of the standardized unit to report humoral immunogenicity could facilitate future cross-platform or cross-lab comparison. The study participants of both vaccines are mainly Taiwanese, reporting in IU/mL could follow cross-ethnicity comparison.

There are a few limitations of this study, first, the design is not randomized, double blinded, but an external comparison, which will compromise the level of evidence. Second, the cell-medicated immunity was not included in the comparative immunogenicity profile. Third, other characterizations that are of interests, including the waning immunity of both vaccines, the cross-reactivity against Variants of Concern (VoCs), were not explored.

The data presented in the study showed that it is reasonably likely that the vaccine efficacy of MVC-COV1901 is similar or superior to that of AZ. The data could be used in support of further vaccine development and regulatory approval.

Author Contributions: Conceptualization, C.-Y. C. and I.-F. L.; methodology, I.-F. L.; software,

226	Acknowledgements:	The study was	funded by Medigen	Vaccine Biologics (s	tudy sponsor) and the
-----	-------------------	---------------	-------------------	----------------------	-----------------------

- 227 Taiwan Centres for Disease Control, Ministry of Health and Welfare.
- 228

230	C'	Y. C. and IF. L.; validation, SY. K., CP. C., and YC. L.; formal analysis, CY. C., IF. L.,
231	and	J.A.G.E.; investigation, CY. C. and SH. C.; resources, CY. C., HC. H., HW. Y. and SH.
232	C.;	data curation, IF. L. and J.A.G.E.; writing-original draft preparation, CY. C. and J.A.G.E.;
233	wri	ting-review and editing, IF. L.; visualization, J.A.G.E and IF. L.; supervision, IF. L.; project
234	adn	ninistration, CY. C. All authors have read and agreed to the published version of the manuscript.
235		
236	Cor	npeting Interests: J.A.G.E. is an employee of Medigen Vaccine Biologics (Taipei, Taiwan) and
237	he l	nas received grants from Taiwan Centres for Disease Control, Ministry of Health and Welfare,
238	dur	ing the conduct of the study. All other authors declare no conflict of interest.
239		
240	Ref	erences
241	1.	Kuo TY, Lin MY, Coffman RL, et al. Development of CpG-adjuvanted stable prefusion
242		SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep, 2020; 10:20085.
243	2.	Taiwan Centers for Disease Control. Taiwan National Infectious Disease Statistics System.
244		Available at: https://nidss.cdc.gov.tw/en/nndss/Cdcwnh07?id=19CoV. Accessed October 7,
245		2021.
246	3.	Ministry of Health and Welfare, Taiwan. News release on June 10th, 2021 on EUA approval
247		criteria for locally developed COVID-19 vaccine (In Traditional Chinese). June 10, 2021.
248		Available at: . <u>https://www.mohw.gov.tw/fp-5017-61305-1.html</u> . Accessed October 7, 2021.

- 249 4. Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC,
- Lee YL, Lin YL. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted
- 251 SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale,
- double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. The Lancet Respiratory
- 253 Medicine. 2021 Oct 13.
- 5. Blanchard B and Lee Y. "Taiwan approves Medigen's COVID-19 vaccine candidate". July 19,
- 255 2021. Available at:
- 256 <u>https://www.reuters.com/world/asia-pacific/taiwan-approves-production-medigens-covid-19-va</u>
- 257 <u>ccine-candidate-2021-07-19/</u>". Accessed September 17, 2021.
- 258 6. International Coalition of Medicines Regulatory Authorities. ICMRA COVID-19 Vaccine
- development: Future steps Workshop. June 24, 2021. Available at:
- 260 <u>http://www.icmra.info/drupal/en/covid-19/24june2021</u>. Accessed October 7, 2021.
- 261 7. Hannah B. European Pharmaceutical Review. "Immuno-bridging studies are sufficient for
- authorising new COVID-19 vaccines, say regulators". September 16, 2021. Available at:
- 263 https://www.europeanpharmaceuticalreview.com/news/162653/immuno-bridging-studies-are-su
- 264 <u>fficient-for-authorising-new-covid-19-vaccines-say-regulators/</u>. Accessed October 7, 2021.
- 8. Medicines and Healthcare products Regulatory Agency, UK. Access Consortium: Alignment
- with ICMRA consensus on immunobridging for authorising new COVID-19 vaccines.
- 267 September 15, 2021. Available at:

268		https://www.gov.uk/government/publications/access-consortium-alignment-with-icmra-consens
269		us-on-immunobridging-for-authorising-new-covid-19-vaccines/access-consortium-alignment-wi
270		th-icmra-consensus-on-immunobridging-for-authorising-new-covid-19-vaccines. Accessed
271		October 7, 2021.
272	9.	MVC-COV1901 COVID-19 vaccine package insert. Medigen Vaccine Biologics Corp., Taipei,
273		Taiwan. 2021.
274	10.	Therapeutic Goods Administration, Australia. Access Consortium: Alignment with ICMRA
275		consensus on immunobridging for authorising new COVID-19 vaccines. September 14, 2021.
276		Available at:
277		https://www.tga.gov.au/access-consortium-alignment-icmra-consensus-immunobridging-authori
278		sing-new-covid-19-vaccines. Accessed February 15, 2022.
279		
280		
281		
282		
283		
284		
285		
286		

287 Tables

288

289 Table 1. Demographics of the population groups

	<65	years	All ages				
Item\MVC lot	AstraZeneca ChAdOx1 nCoV-19	MVC-COV1901 PPI subset	AstraZeneca ChAdOx1 nCoV-19	MVC- COV1901 PPI subset			
	N = 194	N=682	N = 200	N=903			
·Age (years)							
Mean (SD)	42.2 (11.1)	38.02 (11.03)	42.9 (11.7)	45.68 (16.64)			
Median (IQR)	41(16.75)	37.0 (17.0)	41.5(17.2)	42.0 (32.0)			
Min~Max	22.0~64.0	20.0~64.0	22.0~69.0	20.0~ 87.0			
Gender							
Male	78 (40.2)	386 (56.6)	80 (40.0)	521 (57.7)			
Female	116 (59.8)	296 (43.4)	120 (60.0)	382 (42.3)			
□BMI (kg/m ²)							
Mean (SD)	25.3 (4.5)	24.9 (4.3)	25.2(4.6)	24.9 (4.1)			
Median (IQR)	254.6 (5.97)	24.3 (5.7)	24.5(5.97)	24.4 (5.3)			
Min~Max	16.6~39.6	14.3~45.2	17.01~37.5	17.7 ~36.9			
□BMI group							
$<30 \text{ kg/m}^2$	159 (81.96)	594 (87.1)	798 (88.4)	164 (82.0)			
$>=30 \text{ kg/m}^2$	35 (18.04)	88 (12.9)	105 (11.6)	36 (18.0)			
Pre-vaccination neutralizing antibody status							
Seropositive	2 (1.03)	8 (1.17)	2 (1.0)	10 (1.11)			
Seronegative	192 (98.97)	674 (98.83)	198 (99.0)	893 (98.9)			
Comorbidity Category							
at least one comorbidity	74 (38.1)	89 (13.0)	123 (61.5)	729 (80.7)			
No comorbidity	120 (61.9)	593 (87.0)	77 (38.5)	174 (19.3)			

291 Table 2. Neutralizing antibody titer in subjects immunized with either two doses of AZD1222 or

	<65 years*		All ages			
Item\MVC lot	AstraZeneca ChAdOx1 nCoV-19	MVC-COV1901	p-value	AstraZeneca ChAdOx1 nCoV-19	MVC-COV1901	p-value
		PPI subset			PPI subset	
	N = 192	N = 674		N = 198	N = 893	
GMT	185.97	723.6		184.05	654.07	
95% CI of GMT	167.3~206.7	683.7~765.8		166.5~204.7	620.9~689.03	
GMT Ratio	3.89			3.55		
95% CI of GMT Ratio	3.45~4.4		<0.0001	3.2~3.97		<0.0001
Adjusted GMT Ratio (MVC/AZ)	3.78		<0.0001	3.8		<0.0001
95% CI of Adjusted GMT Ratio	3.3~4.3			3.4~ 4.3		

292 MVC-COV1901 in all ages and ages 20-64 years at Day 57 (28 days after the second dose)

*The GMT Ratio was adjusted for age, gender, BMI, and comorbidity profile using general linear models.

293

294

295 Table 3. Worst modified PPI subset of neutralizing antibody titer in subjects immunized with either two

doses of AZD1222 or MVC-COV1901 in all ages and ages 20-64 years at Day 57

<65 years* All ages	
---------------------	--

Item\MVC lot	AstraZeneca ChAdOx1 nCoV-19	MVC-COV1901 PPI subset	p-value	AstraZeneca ChAdOx1 nCoV-19	MVC-COV1901 PPI subset	p-value
	N = 192	N = 458		N = 198	N = 635	
GMT	185.97	492.6		184.05	453.7	
95% CI of GMT	167.3~206.7	470.1~516.1		166.5~204.7	433.8~474.7	
GMT Ratio (MVC/AZ)	2.65		<0.0001	2.46		<0.0001
95% CI of GMT Ratio	2.4~2.97			2.2~2.7		
Adjusted GMT Ratio (MVC/AZ)	2.6		-0.0001	2.62		-0.0001
95% CI of Adjusted GMT Ratio	2.3~2.9		<0.0001	2.3~2.9		<0.0001

* The GMT Ratio was adjusted for age, gender, BMI, and comorbidity profile using general linear models.

297 Figures







300 Figure 1. Neutralizing antibody titer in subjects immunized with two doses of either AZD1222 or

301 MVC-COV1901 in all ages (left) and ages 20-64 years (right)

302 Serum samples were taken before the first vaccination (pre) or 28 days (post) after the second dose of either

303 vaccine and were subjected to live SARS-CoV-2 neutralization assay. The results are shown as 50%

304 neutralizing titer (NT₅₀) with symbols indicating individual NT₅₀ values and the bars indicating the GMT of

- 305 each group.
- 306
- 307



Figure 2. Reverse Cumulative Distribution Curve using log-transformed titers by percent of subjects whohad neutralizing antibody titers 28 days following the second dose of AZ and MVC

All ages

20-64 years



NT₅₀ GMT

